| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23045 |
| Drug |
Brexucabtagene Autoleucel |
| Brand |
Tecartus® |
| Indication |
Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
| Rapid review commissioned |
24/07/2023 |
| Rapid review completed |
10/08/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brexucabtagene autoleucel compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/08/2023 |
| Pre-submission consultation with Applicant |
09/10/2023 |
| Full submission received from Applicant |
18/01/2024 |
| Preliminary review sent to Applicant |
18/09/2024 |
| NCPE assessment re-commenced |
17/10/2024 |
